Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc. (ACRS)
Filing Type: Form 8-K (Current Report)
Report Date: May 7, 2026
Reporting Period: Quarter ended March 31, 2026
Context: The registrant issued a press release announcing financial results for the quarter ended March 31, 2026, furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific financial data. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only indicates that results for the quarter ended March 31, 2026, were announced.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2026) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical or commercial drivers mentioned in the press release for the quarter ended March 31, 2026.
- Check for any updated forward-looking guidance or liquidity runway projections in the full press release.
- Confirm if the "Results of Operations" disclosure in Item 2.02 triggers any specific non-GAAP reconciliations in the full exhibit.